CICS-UBI - Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal.
Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal; Inov4Agro, Institute for Innovation, Capacity Building, and Sustainability of Agri-food Production, Vila Real, Portugal.
Trends Pharmacol Sci. 2024 Sep;45(9):781-797. doi: 10.1016/j.tips.2024.07.004. Epub 2024 Aug 24.
Human papillomaviruses (HPVs) are well-known causative agents of several cancers, yet selective therapies remain under investigation. Nanoparticles, for instance, are emerging as promising solutions to enhance the delivery and efficacy of therapeutic approaches. Despite the increasing number of nanotherapies offering advantages over current treatments, only one has advanced to clinical trials. This review highlights recent advances in nanotherapies for HPV-associated cancers, focusing on the delivery of small molecules, gene-targeted therapies, and vaccines. Some of the challenges faced in nanotherapies translation for clinical application are discussed, emphasizing the most used preclinical models that fail to accurately predict human responses, thereby hindering proper evaluation of nanotherapies. Additionally, we explore and discuss alternative promising new preclinical models that could pave the way for more effective nanotherapeutic evaluations.
人乳头瘤病毒（HPV）是多种癌症的已知致病因子，然而选择性治疗方法仍在研究中。例如，纳米颗粒作为增强治疗方法的递送和疗效的有前途的解决方案而出现。尽管越来越多的纳米疗法比当前的治疗方法具有优势，但只有一种方法已经进入临床试验。本综述强调了 HPV 相关癌症的纳米疗法的最新进展，重点介绍了小分子、基因靶向疗法和疫苗的递送。讨论了纳米疗法转化为临床应用所面临的一些挑战，强调了最常用的临床前模型无法准确预测人类反应，从而阻碍了对纳米疗法的适当评估。此外，我们还探讨和讨论了替代有前途的新临床前模型，这些模型可能为更有效的纳米治疗评估铺平道路。
